{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:42:23Z","timestamp":1782319343132,"version":"3.54.5"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2017_EKES.33"],"award-info":[{"award-number":["2017_EKES.33"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113643"],"award-info":[{"award-number":["70113643"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP15cm0106056"],"award-info":[{"award-number":["JP15cm0106056"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP16ck0106073"],"award-info":[{"award-number":["JP16ck0106073"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ck0106250"],"award-info":[{"award-number":["JP19ck0106250"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19cm0106501"],"award-info":[{"award-number":["JP19cm0106501"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["15H05909"],"award-info":[{"award-number":["15H05909"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["15H05912"],"award-info":[{"award-number":["15H05912"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP26221308"],"award-info":[{"award-number":["JP26221308"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP26253060"],"award-info":[{"award-number":["JP26253060"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ebiom.2021.103327","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T01:13:24Z","timestamp":1618362804000},"page":"103327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial"],"prefix":"10.1016","volume":"66","author":[{"given":"K.","family":"Hoyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hablesreiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Briest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Christen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Kakiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yoshizato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.","family":"Striefler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bischoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Lohneis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Putter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Keilholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bullinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Pelzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Riess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5553-1173","authenticated-orcid":false,"given":"F.","family":"Damm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ebiom.2021.103327_bib0001","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non\u2013small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"issue":"9496","key":"10.1016\/j.ebiom.2021.103327_bib0002","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicenter study (Iressa survival evaluation in lung cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103327_bib0003","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"7424","key":"10.1016\/j.ebiom.2021.103327_bib0004","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature11547","article-title":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes","volume":"491","author":"Biankin","year":"2012","journal-title":"Nature"},{"issue":"7540","key":"10.1016\/j.ebiom.2021.103327_bib0005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"issue":"7592","key":"10.1016\/j.ebiom.2021.103327_bib0006","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"issue":"29","key":"10.1016\/j.ebiom.2021.103327_bib0007","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.2017.72.6463","article-title":"CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial","volume":"35","author":"Sinn","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9791","key":"10.1016\/j.ebiom.2021.103327_bib0008","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(10)62307-0","article-title":"Pancreatic cancer","volume":"378","author":"Vincent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2021.103327_bib0009","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1038\/ncomms8686","article-title":"Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients","volume":"6","author":"Sausen","year":"2015","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.ebiom.2021.103327_bib0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.21037\/atm.2016.05.11","article-title":"Pancreatic cancer from bench to bedside: molecular pathways and treatment options","volume":"4","author":"Kosmidis","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ebiom.2021.103327_bib0011","unstructured":"GeneDx. Pancreatic cancer panel. 2016 (accessed 12.07.2016)."},{"issue":"10","key":"10.1016\/j.ebiom.2021.103327_bib0012","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1182\/blood-2018-05-852822","article-title":"Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients","volume":"133","author":"Christen","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ebiom.2021.103327_bib0013","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/s41375-018-0047-7","article-title":"Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis","volume":"32","author":"Arends","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ebiom.2021.103327_bib0014","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/leu.2016.359","article-title":"EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia","volume":"31","author":"Young","year":"2017","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.ebiom.2021.103327_bib0015","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103327_bib0016","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Royal Stat Soc Ser B"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103327_bib0017","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41591-018-0323-0","article-title":"Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions","volume":"25","author":"Teixeira","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ebiom.2021.103327_bib0018","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41467-019-13892-x","article-title":"Single-cell analysis based dissection of clonality in myelofibrosis","volume":"11","author":"Mylonas","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2021.103327_bib0019","article-title":"Deciphering programs of transcriptional regulation by combined deconvolution of multiple omics layers","author":"H\u00fcebschmann","year":"2017","journal-title":"bioRxiv"},{"issue":"10","key":"10.1016\/j.ebiom.2021.103327_bib0020","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/ng.438","article-title":"Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4","volume":"41","author":"Prickett","year":"2009","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103327_bib0021","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A landscape of pharmacogenomic interactions in cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103327_bib0022","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jhep.2011.07.018","article-title":"GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation","volume":"56","author":"Nault","year":"2012","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103327_bib0023","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ccell.2018.02.003","article-title":"Loss of KDM6A activates super-enhancers to induce gender-specific squamous-like pancreatic cancer and confers sensitivity to BET inhibitors","volume":"33","author":"Andricovich","year":"2018","journal-title":"Cancer Cell"},{"issue":"35","key":"10.1016\/j.ebiom.2021.103327_bib0024","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1200\/JCO.2011.35.5263","article-title":"First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors","volume":"29","author":"Yap","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103327_bib0025","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103327_bib0026","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/bjc.2012.495","article-title":"EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104","volume":"108","author":"Boeck","year":"2013","journal-title":"Br J Cancer"},{"issue":"18","key":"10.1016\/j.ebiom.2021.103327_bib0027","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1158\/0008-5472.CAN-16-0123","article-title":"JNK pathway activation modulates acquired resistance to EGFR\/HER2-targeted therapies","volume":"76","author":"Manole","year":"2016","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.ebiom.2021.103327_bib0028","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1158\/1078-0432.CCR-19-3034","article-title":"TP53 Mutations predict sensitivity to adjuvant gemcitabine in patients with pancreatic ductal adenocarcinoma: next-generation sequencing results from the CONKO-001 trial","volume":"26","author":"Sinn","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.ebiom.2021.103327_bib0029","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ebiom.2021.103327_bib0030","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1158\/1535-7163.MCT-11-0269","article-title":"Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy","volume":"10","author":"Kim","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103327_bib0031","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.ebiom.2021.103327_bib0032","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1593\/neo.111016","article-title":"Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma","volume":"13","author":"Conradt","year":"2011","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.ebiom.2021.103327_bib0033","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1158\/2159-8290.CD-20-0519","article-title":"Epigenetic and transcriptional control of the epidermal growth factor receptor (EGFR) regulates the tumor immune microenvironment in pancreatic cancer","volume":"11","author":"Li","year":"2021","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103327_bib0034","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ccell.2019.03.002","article-title":"Complete regression of advanced pancreatic ductal adenocarcinomas upon combined inhibition of EGFR and C-RAF","volume":"35","author":"Blasco","year":"2019","journal-title":"Cancer Cell"},{"issue":"25","key":"10.1016\/j.ebiom.2021.103327_bib0035","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ebiom.2021.103327_bib0036","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.19.00946","article-title":"Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update","volume":"37","author":"Khorana","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103327_bib0037","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.annonc.2020.10.601","article-title":"A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma","volume":"32","author":"Nicolle","year":"2021","journal-title":"Ann Oncol"},{"issue":"269","key":"10.1016\/j.ebiom.2021.103327_bib0038","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103327_bib0039","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio Cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421001201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421001201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:04:53Z","timestamp":1762455893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396421001201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":39,"alternative-id":["S2352396421001201"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103327","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103327","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103327"}}